Tumor endothelial cell membrane

The **tumor endothelial cell membrane** refers to the collective plasma membranes of endothelial cells that line blood vessels within tumors. These membranes are not a single molecular target but rather a complex and heterogeneous mixture of proteins, lipids, and carbohydrates specific to the tumor vasculature. Tumor endothelial cells (TECs) differ from normal endothelial cells in their gene expression profiles, chromosomal stability, and functional properties. They often display abnormal angiogenic activity to support tumor growth and metastasis[3][7]. TECs can express stem-like markers such as CD90, Sca‑1, MDR1 ALP, Oct‑4 as well as classical vascular markers like CD31 and VEGFR2; they also show increased proliferative capacity and resistance to therapy[3][5]. The TEC membrane is involved in processes such as immune evasion/modulation—by expressing or upregulating molecules like VCAM1/ICAM1—and contributes to the abnormal structure and function of tumor blood vessels including increased permeability and irregular vessel formation[1][4].\n\nWhile certain proteins on the tumor endothelium—such as VEGFR2 or VCAM1—are considered therapeutic targets for antiangiogenic therapies or immunomodulation strategies in cancer treatment[6], "tumor endothelial cell membrane" itself is not a single defined molecular entity or canonical drug target. Instead it represents a broad category encompassing many potential targets expressed on these specialized cells.\n\nBecause this term does not refer to one specific molecule but rather an entire class of cellular membranes with diverse components—and because it lacks standardization—it should be flagged as incorrect for use as a canonical therapeutic target name.

Other names

Tumor endothelial cell (TEC) membraneTEC plasma membraneEndothelial cell membrane in tumor microenvironment